Navigation Links
Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections
Date:12/12/2012

Vancouver, BC, Canada (PRWEB) December 12, 2012

The MRSAid photodisinfection project, an innovative non-pharmaceutical pilot program conducted over the course of 12 months at Vancouver General Hospital (VGH), has proven successful in reducing surgical site infections (SSIs) by 39 per cent, according to results released by VGH. Under this innovative project, patients undergoing major surgeries at VGH, including cardiac, spinal, orthopedic, thoracic, vascular, breast reconstruction, and neurological surgeries, were treated with MRSAid nasal decolonization therapy prior to surgery. Photodisinfection therapy combined with chlorhexidine body wipes were shown to significantly decrease a patient’s load of Methicillin resistant staphylococcus aureus (MRSA) and Methicillin sensitive staphylococcus aureus (MSSA) on their skin and in their nasal cavity. The pilot is the first of its kind and has saved the Vancouver General Hospital an estimated $1.9 million in costs associated with treating patients who develop SSIs.

“By using these two therapies in conjunction, we were able to reduce SSI occurrences by 39 per cent over the study’s duration which marks impressive gains for patient quality and safety,” said Dr. Elizabeth Bryce, Regional Medical Director, Infection Control at Vancouver Coastal Health. “Most importantly, the decrease in SSIs translates into less morbidity for our patients.”

Patients that develop infections after surgery are five times more likely to be readmitted to a hospital, and twice as likely to die. On average, SSIs require an extended hospital stay of eight days in an acute care setting, and adds hundreds of millions of dollars in additional costs to the Canadian healthcare system every year. The MRSAid photodisinfection pilot which treated more than 5000 patients saw a decrease in SSIs from 4 to 1.25 cases per month, resulting in the freeing of 533 patient beds and an addition of 138 surgeries performed. During the course of the study actual occurrences of SSIs dropped from 85 to 50 cases.

“The results of this project mark a global first for photodisinfection as a non-antibiotic approach to significant reductions in surgical site infections, one of the leading sources of healthcare associated infections,” said Carolyn Cross, Chairman and CEO of Ondine Biomedical Inc., the global leader of photodisinfection technologies. “As a partner in this initiative, we want to thank the dedicated team members at VGH for their pioneering work in the field of non-antibiotic infection control and patient safety, and for their willingness to champion innovation and change.”

Preliminary results on MRSAid nasal decolonization have been presented at two infectious disease conferences. Dr. Titus Wong and his team at Vancouver General Hospital (VGH) won the John Conly Innovation Academy Award at the AMMI - CACMID Annual Conference for their implementation of a universal nasal decolonization program.

“We are proud to be the first hospital in Canada and in North America to implement a program using this combined approach of innovative light-activated technology that will prevent patients from contracting infections post-surgery,” said Dr. Titus Wong, Medical Microbiologist, Vancouver General Hospital. “Not only will this new approach prevent infections and reduce costs, but it will also allow us to reinvest that saved money into direct patient care.”

###
About Ondine Biomedical Inc.
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company's website at: http://www.ondinebio.com and http://www.ondineblog.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

About Vancouver Coastal Health
Vancouver Coastal Health provides a full range of health care services, ranging from hospital treatment to community-based residential, home health, mental health and public health services. VCH is responsible for the delivery of $3 billion in care to residents of Vancouver, North Vancouver, West Vancouver, Richmond, and in the coastal mountain communities. http://www.vch.ca.

Read the full story at http://www.prweb.com/releases/OndineBio/12/prweb10229844.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
2. SPIE Urges Congress, President to Avoid Fiscal Cliff and Support Science and Technology to Strengthen Economy
3. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
4. A Sewage Treatment Plant Goes Underground Using In-Pipe Technology Company, Inc. Bioaugmentation
5. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
6. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
7. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
8. Global Agricultural Biotechnology Industry
9. Fast forward to the past: NASA technologists test game-changing data-processing technology
10. Researchers improve technology to detect hazardous chemicals
11. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):